pd_08e_banner

Short Stature Assessment in Children: A Fundamental Step Toward Early Diagnosis of Growth Failure and a Comprehensive Approach to Growth Disorders

View Activity

PROGRAM OVERVIEW

This case-based enduring activity will cover the diagnosis, treatment and management of children with growth/growth hormone disorders.

TARGET AUDIENCE

This activity is intended to meet the educational needs of pediatric nurse practitioners (PNPs) and other pediatric-focused advanced practice registered nurses (APRNs).

LEARNING OBJECTIVES

Upon completion of the program, attendees should be able to:

  • Review methods to measure and plot height and to calculate height velocity and midparental target height to allow early diagnosis of growth disorders in pediatric patients
  • Identify diagnostic criteria that allow differentiation among various causes of growth deficiency
  • Identify tools for better communication with patients and families and coordination of multidisciplinary care
  • Discuss challenges in the referral to specialists for the diagnosis of growth hormone deficiency or other diseases responsible for short stature and their appropriate management

NURSING ACCREDITATION STATEMENT

This program is accredited for 1.0 NAPNAP CE contact hours per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

FACULTY

Jan M. Foote, DNP, ARNP, CPNP
Pediatric Nurse Practitioner
Blank Children’s Endocrinology Clinic
Des Moines, IA
Adjunct Clinical Associate Professor
College of Nursing
The University of Iowa
Iowa City, IA

Mitchell E. Geffner, MD
Chief of the Center for Endocrinology, Diabetes, and Metabolism
Children’s Hospital Los Angeles
Professor of Pediatrics
Keck School of Medicine
University of Southern California
Los Angeles, CA

CME Content Review
The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

DISCLOSURE POLICY STATEMENT

Med Learning Group requires that faculty participating in any CE/CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLOSURE OF CONFLICTS OF INTEREST

Course Chair – – Dr. Foote has research contracts with Endo Pharmaceuticals and Novo Nordisk. She is on the Speaker’s Bureau for Genentech and Abbvie and also received an honorarium from Novo Nordisk as a co-author of a CME newsletter.
Faculty – – Dr. Geffner receives research grant funding from Eli Lilly Inc. and has research contracts with Novo Nordisk and Versartis. He is also a clinical trial consultant for Daiichi-Sankyo, receives royalties from McGraw-Hill and UpToDate, and serves on Advisory Boards for Ipsen, Pfizer, Inc., and Sandoz, and on the Data Safety Monitoring Board for Tolmar. He has also served as a lecturer for Sandoz.

The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group has nothing to disclose.
Brooke Hefele, Outcomes Coordinator for Med Learning Group has nothing to disclose.
Joseph Chebli, PharmD, MA, Director, Scientific and Medical Services for Med Learning Group has nothing to disclose.
Lisa Dorin, Program Manager for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE/CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CE/CME credit for this enduring activity. To receive CE/CME credit participants must:
1. Read the CE/CME information and faculty disclosures.
2. Participate in the enduring activity.
3. Submit the evaluation form to the Med Learning Group.

You will receive your certificate via email within 30 days.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

DISCLAIMER

Med Learning Group makes every effort to develop CE/CME activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CE questions, please contact: NAPNAP at arojas@napnap.org
Contact this CE provider at med Learning Group for privacy and confidentiality policy statement information at http://www.medlearninggroup.com/privacy-policy/

COURSE VIEWING REQUIREMENTS

PC: Internet Explorer (v6 or greater), or Firefox

MAC: Safari

RELEASE DATE: April 5, 2016

EXPIRATION DATE: April 4, 2017

MEDIUM: Internet

COURSE TOPIC: Growth/growth hormone disorders

Estimated Time to Complete This Educational Activity: 60 minutes

View Activity